LivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) P/E ratio
As of 5 November 2026, LivaNova PLC (LIVN) trades at a P/E ratio of 25.6×. Over the past ten years it has ranged from 0.0× (March 2026) to 1,073× (October 2023); the current reading is higher than 84% of that period. That is in line with the Medical Devices industry median of 25.6× and in line with the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 39.9× | (74.72%) |
| FY2023 | 158× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 21.3× | (10.45%) |
| Jun 2026 | 23.8× | (26.13%) |
| Mar 2026 | 32.3× | — |
| Dec 2025 | 0.0× | — |
| 45 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEOG Neogen Corporation compare | n/m |
| BRKR Bruker Corporation compare | n/m |
| AXGN AxoGen, Inc. compare | n/m |
| IRTC iRhythm Holdings, Inc. compare | n/m |
| TXG 10x Genomics compare | n/m |
| BIO Bio-Rad Laboratories, Inc. compare | 9.7× |
| LIVN LivaNova PLC | 25.6× |
| ITGR Integer Holdings Corporation compare | 42.2× |
| HAE Haemonetics Corporation compare | 54.5× |
| Medical Devices industry median | 25.6× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on LIVN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement